These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 29957909)

  • 1. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
    Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
    BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
    Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
    Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval Process: An Overview of Biosimilars in the Oncology Setting.
    Sowinski-Raff L
    Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical specialists' attitudes to prescribing biosimilars.
    Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nursing Roles: Clinical Implications Regarding Trends, Administration, and Education for Biosimilars in Oncology Practice.
    Zack E
    Clin J Oncol Nurs; 2018 Oct; 22(5):21-26. PubMed ID: 30239530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obstacles to Biosimilar Acceptance and Uptake in Oncology: A Review.
    Mroczek DK; Hauner K; Greene GJ; Kaiser K; Peipert JD; Golf M; Kircher S; Shaunfield S; Lylerohr M; Cella D
    JAMA Oncol; 2024 Jul; 10(7):966-972. PubMed ID: 38814582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.